2seventy bio (NASDAQ:TSVT) Receives Sell (E+) Rating from Weiss Ratings

Weiss Ratings reiterated their sell (e+) rating on shares of 2seventy bio (NASDAQ:TSVT) in a research report released on Saturday morning,Weiss Ratings reports.

2seventy bio Trading Up 7.0 %

Shares of NASDAQ:TSVT opened at $2.61 on Friday. 2seventy bio has a twelve month low of $2.35 and a twelve month high of $6.40. The company has a market cap of $134.65 million, a PE ratio of -1.40 and a beta of 1.76. The company’s 50 day moving average is $3.24 and its 200 day moving average is $4.14.

Institutional Trading of 2seventy bio

Hedge funds have recently modified their holdings of the stock. Geode Capital Management LLC raised its position in 2seventy bio by 1.1% during the third quarter. Geode Capital Management LLC now owns 1,176,244 shares of the company’s stock valued at $5,553,000 after acquiring an additional 13,144 shares in the last quarter. State Street Corp increased its holdings in shares of 2seventy bio by 1.5% during the 3rd quarter. State Street Corp now owns 1,058,773 shares of the company’s stock valued at $4,997,000 after purchasing an additional 15,638 shares in the last quarter. Marshall Wace LLP lifted its stake in shares of 2seventy bio by 50.4% in the 2nd quarter. Marshall Wace LLP now owns 667,023 shares of the company’s stock valued at $2,568,000 after purchasing an additional 223,408 shares during the period. Western Standard LLC purchased a new stake in 2seventy bio during the third quarter worth $1,350,000. Finally, Wellington Management Group LLP grew its position in 2seventy bio by 9.0% during the third quarter. Wellington Management Group LLP now owns 262,040 shares of the company’s stock valued at $1,237,000 after buying an additional 21,673 shares during the period. Hedge funds and other institutional investors own 93.90% of the company’s stock.

2seventy bio Company Profile

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.